Cancer patients who contracted COVID-19 during the height of the pandemic in New York City had similar outcomes to other patients with COVID-19, a study from researchers at Weill Cornell Medicine and NewYork-Presbyterian has found. The findings suggest that in the absence of other risk factors for poor COVID-19 outcomes, patients with cancer may be able to safely continue treatment during the pandemic.
EIPM Embraces Entrepreneurship
November 5, 2020
EIPM to Study Cancer Genetics Among Underserved
October 16, 2020
Drawing on New York’s diverse population, Weill Cornell Medicine scientists have been awarded grants from the New York Genome Center (NYGC) to study how several types of cancer differ in patients with different genetic backgrounds and point to precision treatments for groups that have been historically underrepresented in cancer research.
New Study Examines Mysteries of COVID-19
October 12, 2020
A study by investigators at Weill Cornell Medicine and NewYork-Presbyterian aims to answer one of COVID-19’s biggest mysteries: why do some people become severely ill, while others have no symptoms? The multidisciplinary team will seek to identify underlying genetic and immune factors that contribute to these varying outcomes to help guide the development of precision prevention and treatment efforts.
EIPM October 2020 External Newsletter
October 6, 2020
The EIPM External Newsletter below is sent quarterly to people who sign-up on our website.
Dear Friends of the EIPM:
During these extraordinary times we have continued to create breakthroughs in basic research that will benefit patients with cancer, metabolic disease, neurologic impairments, and many more conditions. Our researchers have also worked collaboratively with investigators across the country and around the world to unlock the mysteries of Covid-19, and contribute to new treatments and therapies for patients.
How Tumors Extensively Rewrite Their DNA
October 5, 2020
Cancer cells rearrange, copy, and delete their DNA in complex but distinct patterns, according to new research from a multi-institution team led by investigators at Weill Cornell Medicine and the New York Genome Center. The investigators developed sophisticated new algorithms to analyze nearly 3,000 genome sequences from human tumors.
EIPM Investigators Earn NYGC Grants
September 11, 2020
Leading cancer scientists working with the New York Genome Center (NYGC) announced today that grants are being awarded to fund six projects that address the role of ethnicity in several major cancer types, taking advantage of the diversity of patients being treated at health care institutions throughout the New York City area.
[See New York Times coverage of the New York Genome Center grants.]
New Approaches to Breast Cancer Treatment
September 2, 2020
A preclinical model of a common type of breast cancer provides new insight into why an immunotherapy known as checkpoint inhibition has not yet been effective against the cancer, according to researchers from Weill Cornell Medicine. Research with the model also suggests new approaches to treatment.
Dr. Leonard Named Associate Dean
August 28, 2020
Dr. John Leonard, an esteemed physician-scientist who specializes in lymphoma research and treatment, has been named senior associate dean for innovation and initiatives at Weill Cornell Medicine.
Dr. Lewis Cantley Wins Janssen Award
August 25, 2020
Dr. Lewis Cantley, the Meyer Director of the Sandra and Edward Meyer Cancer Center at Weill Cornell Medicine and NewYork-Presbyterian/Weill Cornell Medical Center, and a Member of the Englander Institute for Precision Medicine, has won the 2020 Dr. Paul Janssen Award for Biomedical Research.